NASDAQ:PHIO Phio Pharmaceuticals Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Phio Pharmaceuticals Corp. Please log in to your account or sign up in order to add this asset to your watchlist. $0.74 +0.02 (+2.78%) (As of 06/28/2022 11:04 AM ET) Add Compare Share Today's Range$0.73▼$0.8050-Day Range$0.65▼$1.3252-Week Range$0.62▼$2.47Volume900 shsAverage Volume173,907 shsMarket Capitalization$10.11 millionP/E RatioN/ADividend YieldN/APrice Target$6.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive PHIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Phio Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address PHIO Stock Forecast (MarketRank)Overall MarketRank™2.03 out of 5 starsAnalyst Opinion: 3.5Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 2.5 5 -4 -3 -2 -1 - 3.5 Analyst's Opinion Consensus RatingPhio Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.00, Phio Pharmaceuticals has a forecasted upside of 710.8% from its current price of $0.74.Amount of Analyst CoveragePhio Pharmaceuticals has received no research coverage in the past 90 days. Previous Next 4.1 Community Rank Outperform VotesPhio Pharmaceuticals has received 33 “outperform” votes. (Add your “outperform” vote.)Underperform VotesPhio Pharmaceuticals has received 21 “underperform” votes. (Add your “underperform” vote.)Community SentimentPhio Pharmaceuticals has received 61.11% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Phio Pharmaceuticals and other stocks. Vote “Outperform” if you believe PHIO will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PHIO will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldPhio Pharmaceuticals does not currently pay a dividend.Dividend GrowthPhio Pharmaceuticals does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Phio Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.30% of the stock of Phio Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 13.15% of the stock of Phio Pharmaceuticals is held by institutions. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Phio Pharmaceuticals are expected to grow by 38.20% in the coming year, from $0.89 to $1.23 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Phio Pharmaceuticals is -0.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Phio Pharmaceuticals is -0.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPhio Pharmaceuticals has a P/B Ratio of 0.46. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Phio Pharmaceuticals (NASDAQ:PHIO)Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on targeting tumor and immune cells by regulating genes of the immune system. The company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1 for immunotherapy in adoptive cell transfer (ACT); PH-894 that silences the epigenetic protein BRD4, which is an intracellular regulator of gene expression for use in ACT; and PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for use in ACT. It has collaborations with AgonOx Inc. on clinical development of novel T cell-based cancer immunotherapies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.Read More PHIO Stock News HeadlinesJune 23, 2022 | americanbankingnews.comAnalyzing F-star Therapeutics (NASDAQ:FSTX) and Phio Pharmaceuticals (NASDAQ:PHIO)June 15, 2022 | americanbankingnews.comPhio Pharmaceuticals Corp. (NASDAQ:PHIO) Given Consensus Recommendation of "Buy" by BrokeragesJune 12, 2022 | americanbankingnews.comPhio Pharmaceuticals Corp. (NASDAQ:PHIO) Receives Average Recommendation of "Buy" from AnalystsJune 8, 2022 | americanbankingnews.comPhio Pharmaceuticals (NASDAQ:PHIO) Stock Rating Upgraded by Zacks Investment ResearchJune 6, 2022 | finance.yahoo.comPhio Pharmaceuticals Presents Study Outline of Its First Clinical Trial with PH-762 for Advanced Melanoma at the 2022 ASCO Annual MeetingMay 16, 2022 | finance.yahoo.comPhio Pharmaceuticals Presents New Data Demonstrating PH-894 Enhances Activity of HER2-CAR-T Cells at ASGCT 2022May 16, 2022 | finance.yahoo.comPhio Pharma's New Preclinical Data Shows PH-894 Enhances Activity of Cancer CAR-T CellsMay 13, 2022 | finance.yahoo.comPhio Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business UpdateMay 5, 2022 | finance.yahoo.comPhio Pharmaceuticals Announces Senior Leadership Personnel ChangeMay 2, 2022 | finance.yahoo.comPhio Pharmaceuticals Announces Upcoming Presentation of PH-894 Data at ASGCT 25th Annual Meeting 2022May 2, 2022 | finance.yahoo.comPhio Pharmaceuticals Announces the Appointment of Patricia A. Bradford to its Board of DirectorsApril 26, 2022 | marketwatch.comPhio Pharma Shares Drop 10% After Opening Enrollment for PH-762 TrialApril 26, 2022 | seekingalpha.comPhio begins enrollment in phase 1b trial of PH-762 to treat skin cancerSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PHIO CUSIPN/A CIK1533040 Webphiopharma.com Phone(508) 767-3861Fax508-767-3862Employees12Year FoundedN/ACompany Calendar Last Earnings5/13/2022Today6/28/2022Next Earnings (Estimated)8/11/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$6.00 High Stock Price Forecast$6.00 Low Stock Price Forecast$6.00 Forecasted Upside/Downside+710.8%Consensus RatingBuy Rating Score (0-4)3 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.920010) Trailing P/E RatioN/A Forward P/E Ratio0.83 P/E GrowthN/ANet Income$-13.29 million Net MarginsN/A Pretax MarginN/A Return on Equity-52.04% Return on Assets-46.47% Debt Debt-to-Equity RatioN/A Current Ratio8.42 Quick Ratio8.42 Sales & Book Value Annual Sales$20 thousand Price / Sales505.42 Cash FlowN/A Price / Cash FlowN/A Book Value$1.62 per share Price / Book0.46Miscellaneous Outstanding Shares13,660,000Free Float13,618,000Market Cap$10.11 million OptionableNot Optionable Beta1.69 Phio Pharmaceuticals Frequently Asked Questions Should I buy or sell Phio Pharmaceuticals stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Phio Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Phio Pharmaceuticals stock. View analyst ratings for Phio Pharmaceuticals or view top-rated stocks. What is Phio Pharmaceuticals' stock price forecast for 2022? 1 brokers have issued 1-year price objectives for Phio Pharmaceuticals' stock. Their PHIO stock forecasts range from $6.00 to $6.00. On average, they predict Phio Pharmaceuticals' stock price to reach $6.00 in the next twelve months. This suggests a possible upside of 710.8% from the stock's current price. View analysts' price targets for Phio Pharmaceuticals or view top-rated stocks among Wall Street analysts. How has Phio Pharmaceuticals' stock performed in 2022? Phio Pharmaceuticals' stock was trading at $1.00 at the beginning of 2022. Since then, PHIO stock has decreased by 26.0% and is now trading at $0.74. View the best growth stocks for 2022 here. Are investors shorting Phio Pharmaceuticals? Phio Pharmaceuticals saw a decline in short interest in the month of June. As of June 15th, there was short interest totaling 246,400 shares, a decline of 33.2% from the May 31st total of 368,700 shares. Based on an average daily trading volume, of 3,440,000 shares, the days-to-cover ratio is currently 0.1 days. Currently, 1.9% of the company's shares are short sold. View Phio Pharmaceuticals' Short Interest. When is Phio Pharmaceuticals' next earnings date? Phio Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022. View our earnings forecast for Phio Pharmaceuticals. How were Phio Pharmaceuticals' earnings last quarter? Phio Pharmaceuticals Corp. (NASDAQ:PHIO) posted its quarterly earnings data on Friday, May, 13th. The company reported ($0.19) earnings per share for the quarter, topping analysts' consensus estimates of ($0.30) by $0.11. View Phio Pharmaceuticals' earnings history. Who are Phio Pharmaceuticals' key executives? Phio Pharmaceuticals' management team includes the following people: Ms. Caitlin Kontulis, VP of Fin. & Admin. and Sec. (Age 36) Who are some of Phio Pharmaceuticals' key competitors? Some companies that are related to Phio Pharmaceuticals include NexImmune (NEXI), Cocrystal Pharma (COCP), Alimera Sciences (ALIM), Astria Therapeutics (ATXS), Ocuphire Pharma (OCUP), Aileron Therapeutics (ALRN), Acurx Pharmaceuticals (ACXP), Oragenics (OGEN), Oragenics (OGEN), Iterum Therapeutics (ITRM), Ampio Pharmaceuticals (AMPE), Ampio Pharmaceuticals (AMPE), Larimar Therapeutics (LRMR), 4D pharma (LBPS) and Ceapro (CRPOF). View all of PHIO's competitors. What other stocks do shareholders of Phio Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Phio Pharmaceuticals investors own include DURECT (DRRX), CymaBay Therapeutics (CBAY), Ocugen (OCGN), Akero Therapeutics (AKRO), Ampio Pharmaceuticals (AMPE), Boxlight (BOXL), Evofem Biosciences (EVFM), Fulcrum Therapeutics (FULC), Jaguar Health (JAGX) and Milestone Pharmaceuticals (MIST). What is Phio Pharmaceuticals' stock symbol? Phio Pharmaceuticals trades on the NASDAQ under the ticker symbol "PHIO." Who are Phio Pharmaceuticals' major shareholders? Phio Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (2.23%), Cetera Investment Advisers (0.66%), Renaissance Technologies LLC (0.30%) and Concourse Financial Group Securities Inc. (0.00%). Company insiders that own Phio Pharmaceuticals stock include Gerrit Dispersyn and Robert L Ferrara. View institutional ownership trends for Phio Pharmaceuticals. Which major investors are buying Phio Pharmaceuticals stock? PHIO stock was acquired by a variety of institutional investors in the last quarter, including Cetera Investment Advisers, Renaissance Technologies LLC, and Vanguard Group Inc.. Company insiders that have bought Phio Pharmaceuticals stock in the last two years include Gerrit Dispersyn, and Robert L Ferrara. View insider buying and selling activity for Phio Pharmaceuticals or or view top insider-buying stocks. How do I buy shares of Phio Pharmaceuticals? Shares of PHIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Phio Pharmaceuticals' stock price today? One share of PHIO stock can currently be purchased for approximately $0.74. How much money does Phio Pharmaceuticals make? Phio Pharmaceuticals (NASDAQ:PHIO) has a market capitalization of $10.11 million and generates $20 thousand in revenue each year. The company earns $-13.29 million in net income (profit) each year or ($0.920010) on an earnings per share basis. How many employees does Phio Pharmaceuticals have? Phio Pharmaceuticals employs 12 workers across the globe. How can I contact Phio Pharmaceuticals? Phio Pharmaceuticals' mailing address is 257 SIMARANO DRIVE SUITE 101, MARLBOROUGH MA, 01752. The official website for Phio Pharmaceuticals is phiopharma.com. The company can be reached via phone at (508) 767-3861, via email at [email protected], or via fax at 508-767-3862. This page (NASDAQ:PHIO) was last updated on 6/28/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
